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ABSTRACT
Colistin is commonly the last resort for treatment of infections caused by multidrug-resistant Gram-
negative bacteria. In clinical practice, it is frequently used as combination therapy in order to improve its
antibacterial activity, despite the consequent increase in toxicity. The available evidence from various
studies (microbiological, animal and clinical studies, retrieved from the PubMed and Scopus databases)
regarding the comparative effectiveness of colistin monotherapy and colistin combination therapy was
evaluated. Most of the microbiological studies examined colistin monotherapy vs. combinations with
rifampicin (nine studies) or carbapenems (three studies) for Pseudomonas aeruginosa or Acinetobacter
baumannii infections. A synergistic effect was detected in all the studies examining the combination of
colistin and rifampicin, whereas carbapenems exhibited a synergistic effect in two of three studies. Most
of the animal studies examined colistin monotherapy vs. combinations with rifampicin, carbenicillin,
piperacillin and imipenem for treatment of P. aeruginosa, A. baumannii or Escherichia coli infections.
Mortality rates were significantly lower in the combination treatment arm in three of six relevant
studies. However, data from the small number (four) of relevant human studies suggest non-inferiority
of colistin monotherapy as compared with combination therapy. In conclusion, microbiological studies
suggest superiority of colistin combination treatment, which is in contrast to preliminary data from
studies in humans. Results from animal study data are equivocal. There is an urgent need for
appropriately designed and powered clinical trials addressing this apparently controversial situation.
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INTRODUCTION
The mounting prevalence worldwide of infections
caused by multidrug-resistant (MDR) Gram-nega-
tive bacteria, in particular Pseudomonas aeruginosa,
Acinetobacter baumannii and Klebsiella pneumoniae,
is causing substantial concern [1]. The lack of
novel antimicrobials for Gram-negative infections
under development, especially for the treatment
of infections due to P. aeruginosa, has forced
clinicians to reappraise the clinical value of
colistin, a polymyxin antibiotic discovered
c. 60 years ago [2–5].
Colistin is a multicomponent polypeptide anti-
biotic, composed mainly of colistin A and colis-
tin B; its use was limited by its renal toxicity, and it
was replaced in the 1970s by antibiotics considered
to be less toxic. Pharmacokinetic and pharmaco-
dynamic information on colistin is limited, perhaps
due to the moderate clinical interest in polymyxins
during the 1980s and 1990s and the difficulties in
accurately measuring colistin and colistimethate
sodium separately in biological samples [3].
More recently, colistin has increasingly been
used as salvage therapy [2,6] in combination with
one or more antibacterials for the treatment of
severe infections in critically ill patients [7].
Despite the fact that polymyxins have been
available for over 50 years, in vitro pharmaco-
dynamic, animal or clinical studies regarding the
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pharmacokinetic parameters (maximal concen-
tration (Cmax) ⁄MIC, area under the curve ⁄MIC
(AUC ⁄MIC), and proportion of time ⁄MIC (%T ⁄
MIC)) of colistin formulations are scarce [8]. In
clinical practice, colistin is usually administered
at 8-h intervals.
The medical community has shown great
interest in the comparative benefit, if any, of
combination therapy vs. monotherapy in the
treatment of Gram-negative and Gram-positive
bacterial infections. Several studies have ques-
tioned the clinical superiority of combination
therapy and have addressed the issues of the
increased toxicity and the increased cost related
to combination treatment regimens [9–13].
However, in severe infections caused by MDR
Gram-negative pathogens, most clinicians would
currently have reservations about colistin mono-
therapy. Moreover, a major concern regarding
colistin monotherapy is the potential problem of
heteroresistance among Gram-negative bacterial
populations exposed to colistin alone [8,14].
Currently, there is a dearth of data regarding
the clinical value of combination therapy and
the clinical impact of heteroresistance. An over-
view of data from in vitro, animal and clinical
studies regarding the efficacy and effectiveness
of colistin combinations vs. colistin alone is
presented in this review. This brief synopsis of
relevant data may contribute to an evaluation of
whether the superiority of colistin combinations,
as compared with colistin alone, as depicted
in in vitro studies, is maintained and verified
in animal and, most importantly, in clinical
studies.
MICROBIOLOGICAL STUDIES
COMPARING COLISTIN
MONOTHERAPY AND
COMBINATION THERAPY
In vitro studies comparing colistin alone and
colistin in combination with other antibiotics
were considered to be relevant to the focus of
this review. A search of the PubMed and Scopus
databases yielded 16 relevant studies [15–30]. The
search terms used were colistin, polymyxin or
colimycin, in vitro study, Acinetobacter, Pseudomo-
nas, Stenotrophomonas maltophilia, and Klebsiella.
One study [20] was excluded because it referred
to polymyxin B. Data retrieved from relevant
studies are presented in Table 1.
In all these studies, susceptibility to colistin was
previously evaluated by determination of MICs.
The activity of the combination of colistin and
other agents was evaluated using the checkerboard
microbroth dilution method in six studies
[15,16,23,25–27]. Concentration–time–kill curves
were used in nine studies [17–19, 21–23,27,28,30].
In one investigation, an Etest study was also
performed [30].
The antimicrobial agents combined with colistin
were rifampicin [15,16,18–19,21,23,26,28,29],
azithromicin [17,24,26], imipenem [27], mero-
penem [17,26], gentamicin [17], piperacillin [17],
ciprofloxacin [17,22,24], co-trimoxazole [19,24],
ceftazidime [22,24], doxycycline [26], minocycline
[30], and the histatin derivative P-113 [25], i.e.
a combination of polypeptides. However, the
antimicrobials most frequently combined with
colistin were rifampicin (ten studies) and carba-
penems (four studies).
The most commonly studied organism was
P. aeruginosa (8 ⁄ 13 studies [17,21–27]). In one
study, Rynn et al. found that the addition of
colistin to other antipseudomonal agents pro-
duced a smaller area under the bactericidal killing
curves, and hence a greater killing effect on
P. aeruginosa, than monotherapy [17]. This effect
was independent of the colistin concentration (0.5
and 5 mg ⁄L, respectively). In another study, two
MDR strains, which were colistin-susceptible,
were studied using a time–kill assay [22]. The
combination of colistin and ceftazidime was
synergistic, with only slight superiority of the
combination with colistin at Cmax 18 mg ⁄L as
compared to the combination with colistin at
Cmax 6 mg ⁄L. Ciprofloxacin added to colistin did
not enhance antibiotic activity.
Tascini et al. compared colistin plus rifampicin
with colistin alone in seven MDR P. aeruginosa
strains on which colistin alone had no bactericidal
effect and after 6 h was unable to counteract
bacterial growth [23]. They found that, in combi-
nation with rifampicin, colistin became bactericidal
and the effect was prolonged for 12 h. Moreover,
the combination resulted in synergy in six of seven
strains. Synergy between colistin and rifampicin
was also confirmed by Timurkaynak et al. in five
MDR A. baumannii strains [26].
However, results were equivocal when carba-
penems were added to colistin [26,27] in the case of
MDR P. aeruginosa. Indeed, in one study [26],
colistin plus meropenem was additive in two of
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five strains and indifferent in the remaining three
strains. In the other study of one MDR strain with
an MIC of colistin of 8 mg ⁄L, synergy was
observed between colistin and imipenem with a
fractional inhibitory concentration index of 0.458
[26].
Regarding the activity under anaerobic and
biofilm conditions, Hill et al. [24] found that colistin
combinations with ciprofloxacin, co-trimoxazole,
ceftazidime or azithromicin enhanced bactericidal
activity against 16 MDR P. aeruginosa strains (all
susceptible to colistin alone). Finally, Giacometti
et al. [25] demonstrated that colistin plus a combi-
nation of peptides (histatin derivative P-113) had
an indifferent effect.
Seven in vitro studies of A. baumannii were
found [15,16,18,26,28–30]; in all of them, colistin
was compared to colistin plus rifampicin, and in
one study [26], other antimicrobials (azithromicin,
doxicycline, and meropenem) were also studied
in combination with colistin. In the study con-
ducted by Hogg et al., all strains were susceptible
to colistin, and 85% (11 ⁄ 13) were resistant to
rifampicin [16]. The combination of colistin plus
rifampicin was synergistic against 85% of isolates
and indifferent in the remaining 15%, whereas no
antagonism was found. In the study conducted by
Giamarellos-Bourboulis et al. [18], which used
time–kill curve assays, 39 MDR A. baumannii
strains (all susceptible to colistin) were studied.
The authors found that the in vitro activity of
colistin was highly increased in the presence
of rifampicin, and the synergy was dependent
on the concentration of colistin (synergy at 24 h of
growth was 51.3% and 66.7% at 1 · MIC and
4 · MIC of colistin, respectively). In the study
conducted by Timurkaynak et al. [26], five MDR
A. baumannii strains (all susceptible to colistin)
were studied, using the checkerboard methodol-
ogy. The combination with rifampicin was fully
synergistic against four of five strains, whereas
the combinations with meropenem and azithr-
omicin were synergistic against three of five
strains each. Interestingly, the combination with
doxycycline was partially synergistic against
four of five strains.
A recent study conducted by Song et al. [28]
showed that colistin alone exhibited a bacterici-
dal effect only at high concentrations (above
4 · MIC), which is clinically important, consid-
ering the dose-dependent nephrotoxicity of colis-
tin. However, they found that colistin plus
rifampicin had synergistic and bactericidal ef-
fects on the MIC level that were sustained for
more than 24 h.
Similarly, Tan et al. [30] found that at 1 · MIC,
neither colistin nor minocycline, when tested
alone, demonstrated considerable bactericidal acti-
vity against MDR-resistant A. baumannii strains,
and that there was also evidence of bacterial
regrowth at 24 h in the presence of both antibiotics,
when tested alone. The use of colistin and mino-
cycline in combination showed a rapidly bacteri-
cidal and synergistic effect, with minimal evidence
of bacterial regrowth at 24 h, when a ‡3 log10
reduction in CFU was obtained. Interestingly, the
Etest results were in disagreement with those of
the time–kill assay.
Two studies comparing the activity of colistin
combination therapy with that of other antimicro-
bial agents against S. maltophilia were found
[19,25]. In one of them, 24 co-trimoxazole ⁄ rifam-
picin-resistant strains with MIC50 and MIC90 for
colistin of 4 and 16 mg ⁄L, respectively, were
tested using colistin alone or in combination with
rifampicin or co-trimoxazole [19]. Synergy be-
tween colistin and rifampicin was observed in
60% of the isolates, and occurred in the first hours
of exposure. Synergy with co-trimoxazole was
found at a colistin concentration of 4 · MIC (25%
of the isolates at 6 h and 41.7% at 24 h of growth).
In conclusion, both interactions prevented
regrowth occurring under colistin monotherapy
after 24 h of growth. Finally, in another study,
Giacometti et al. [25] found an indifferent effect of
the histatin derivative P-113 combined with colis-
tin on 24 MDR S. maltophilia strains.
ANIMAL STUDIES COMPARING
COLISTIN MONOTHERAPY AND
COMBINATION THERAPY
Animal studies comparing the effectiveness of
colistin combination therapy with monotherapy
were considered to be relevant to the focus of
this review. The search of the PubMed and
Scopus databases yielded six relevant studies
[27,31–35]. The search terms used were colistin
or colimycin, in vivo study, animal study, Acinet-
obacter, Pseudomonas, S. maltophilia, and Klebsiella.
Data retrieved from the relevant studies are
presented in Table 2.
P. aeruginosa, A. baumanii and Escherichia coli
were tested in three studies [27,31,35], two studies
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[33,34], and one study [32], respectively. Experi-
mental mouse models were adopted in three
studies [27,31,33] and rat models in the remaining
three [32,34,35]. Colistin was combined with
rifampicin in three studies [33–35], and with
imipenem [27], carbenicillin [31] or piperacillin
[32] in the remaining three studies.
With regard to experimental P. aeruginosa
infections, in an old study, Saslaw et al. [31]
found that the mortality rate in septic monkeys
treated with colistin alone (6 ⁄ 10) did not differ
significantly from that in septic monkeys treated
with colistin plus carbenicillin (5 ⁄ 12). In two
more recent Italian studies [27,35] using an
experimental model of sepsis in rats, Cirioni
et al. [27] found that: (1) overall mortality in
animals treated with colistin alone was 30%
(6 ⁄ 20) vs. 15% (3 ⁄ 20) with colistin plus imipe-
nem; and (2) mortality at 72 h was 60% (9 ⁄ 15)
in animals treated with colistin alone and 27%
(4 ⁄ 15) in animals treated with colistin plus
rifampicin [35]. The latter study was a prospec-
tive, randomized, controlled animal study, and
the authors found that treatment with colistin
1 mg ⁄ kg plus rifampicin 10 mg ⁄ kg resulted in a
significant reduction in bacterial count in perito-
neal fluid as compared with colistin alone, even
though no significant differences were found in
mortality rates between the two groups.
In both of the two experimental MDR
A. baumannii model studies, colistin alone was
compared with colistin plus rifampicin. In the first
study, which used a mouse model of pneumonia,
the endpoint was the lung bacterial count expres-
sed as log10 CFU ⁄ g, mean ± SD, with 8.38 ± 1.22
for colistin alone and 5.59 ± 1.17 for colistin plus
rifampicin; the differences were not statistically
significant [33]. In the second study, which used a
thigh infection model in neutropenic Wistar rats,
the median survival rate was 4 days and the
mortality rate after 6 days was 100% (10 ⁄ 10) with
colistin alone, whereas the median survival was
4 days (the difference between colistin and colistin
plus rifampicin was not statistically significant)
and the mortality rate after 6 days was 70% (7 ⁄ 10)
with colistin plus rifampicin (p 0.018 between
groups) [34].
Finally, in the only study of E. coli (strain
ATCC 25922), Giacometti et al. [32] used an
experimental intraperitoneal infection model in
adult Wistar rats, with uninfected rats as controls.
Mortality with colistin alone at 48 h was 33.3%
(5 ⁄ 15) vs. 0% (0 ⁄ 15) in rats treated with colistin
(1 mg ⁄ kg) plus piperacillin (60 mg ⁄ kg). Similarly,
the intraperitoneal bacterial cell count was 3.4 ·
103 CFU ⁄mL ± (0.9 · 103) with colistin alone vs.
<10 CFU ⁄mL with the combination regimen,
whereas the endotoxin level was almost the same
in the two conditions.
CLINICAL STUDIES COMPARING
COLISTIN MONOTHERAPY AND
COMBINATION THERAPY
Clinical studies comparing the effectiveness of
colistin combination therapy with monotherapy
were considered to be relevant to the focus of this
review. Only four relevant studies were identified
by searching the PubMed and Scopus databases.
The search terms used were colistin or colimycin
in combination with monotherapy, intravenous,
Acinetobacter, Pseudomonas and Klebsiella [36–39].
Data retrieved from relevant studies are pre-
sented in Table 3.
The overall number of patients examined in the
monotherapy treatment arm was 46, whereas the
number of patients in the comparator group was
48. The antimicrobial agents used in combination
with colistin were rifampicin, imipenem, mero-
penem, aztreonam, azlocillin, piperacillin, ceftaz-
idime and ciprofloxacin. The effectiveness of the
various regimens was examined in diabetic foot
infection [36], pneumonia ([37,38]), bacteraemia
[37,38], intra-abdominal infection ([37,38]), endo-
carditis [38], urinary tract infection [37], spondy-
lodiskitis [37], soft tissue infection [37], and
respiratory exacerbations in patients with cystic
fibrosis [39]. The responsible pathogens were
MDR P. aeruginosa [35–39] and A. baumannii [37].
In all four studies identified there were no
statistically significant differences in the effec-
tiveness and safety rates. However, a retrospec-
tive study comparing colistin monotherapy and
combination therapy with meropenem found a
higher survival rate in the monotherapy treat-
ment arm after adjustment for the variables for
which significant differences were noticed [37].
Another study that examined colistin effective-
ness in patients with cystic fibrosis demon-
strated no statistically significant differences
between treatment groups except for higher
C-reactive protein normalization rates in the
combination therapy group by day 12 of treat-
ment [39].
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NON-COMPARATIVE STUDIES OF
COLISTIN MONOTHERAPY AND
COMBINATION THERAPY
As the emergence of MDR strains susceptible only
to colistin poses an important clinical problem, an
increasing number of studies have sought to
assess the clinical effectiveness of colistin. Most
of these studies have been non-comparative and
have examined either colistin combination regi-
mens [7,40–43] or colistin monotherapy [44,45].
In addition, a number of comparative studies
[46–48] have examined the effectiveness of colistin
regimens vs. non-colistin regimens.
A review of the data from noncomparative
studies concerning the clinical effectiveness of
colistin monotherapy and combination therapy
suggests that therapy with colistin alone achieves
cure and ⁄ or improvement rates ranging from
57% to 78%, whereas the equivalent rates for
combination therapy are 67–74%. Despite the
very high similarity between colistin mono-
therapy and combination therapy in rates of
effectiveness, the interpretation of existing data
is hampered by the considerable variability in
settings, dosing regimens and patient populations
among studies. Notably, in a prospective study
conducted by Reina et al. [46], the rates of
improvement reported with colistin mono-
therapy, although comparable to those achieved
in the non-colistin group, were substantially
lower than those reported by the rest of the
relevant studies. Factors contributing to this
discordance include the facts that criteria for
improvement were strictly defined as simulta-
neous normalization of central temperature (38C
or less), white blood cell count (10 000 ⁄mm3 or
less) and PaO2 ⁄ FIO2 (greater than 187) and that
the course of infection was evaluated on day 6,
which may be too early for the examined param-
eters to show improvement.
EVALUATION OF THE AVAILABLE
EVIDENCE
From a review of the available literature, it is
obvious that there have been only a limited
number of studies comparing the clinical effec-
tiveness of colistin monotherapy and combination
therapy in patients with or without cystic fibrosis.
Moreover, the number of patients participating in
the existing studies is markedly low, and addi-
tional limitations stem from the fact that half of
the studies are retrospective and there is hetero-
geneity in the definition of outcome, variability
in the dosing regimens and differences in the
susceptibility testing methods (disk diffusion or
broth dilution).
Despite the evidence of synergy between colis-
tin and various antimicrobial agents (imipenem,
rifampicin, ceftazidime) in a proportion of in vitro
and animal studies, the evidence from the limited
clinical studies available suggests that colistin
combination therapy is not superior to monother-
apy. Also, data from a small retrospective study
[37] conducted in Greece support an association
between colistin monotherapy and better rates of
survival that remained statistically significant
after adjustment for various relevant variables.
Although this study had limitations inherent to
the study design of retrospective studies, it is
interesting that the favourable result with respect
to colistin monotherapy remained statistically
significant even after adjustment for important
clinical characteristics, with differences being
seen in the distribution between the two groups,
i.e. site of infection and responsible pathogen.
However, it should be emphasized that the
favourable outcome of monotherapy reported in
this study may be due to the effect of other
confounding factors not adjusted for in the
multivariate analysis.
It seems that the severity and life-threatening
character of infections caused by MDR patho-
gens has deterred clinicians from providing
colistin monotherapy in a considerable propor-
tion of cases. In addition, it should be empha-
sized that there have not been recent
randomized controlled trials examining the var-
ious aspects of the effectiveness of colistin,
including the comparison of colistin monothera-
py with combination therapy.
Although colistin might be the last resort for
severe infections in critically ill patients, as it
exhibits antimicrobial activity against MDR
Gram-negative pathogens, there is substantial
evidence that it does not escape resistance. Li
et al. [8], in 2006, described the emergence of
A. baumanii subpopulations resistant to colistin,
and A. baumanii heteroresistance to carbapenems
has been detected by Etest in strains isolated in
Greece [49]. As an increase in the daily dosage of
colistin in order to eradicate resistant subpopula-
tions could confer higher toxicity rates, the use of
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combination regimens has been proposed. How-
ever, it is noteworthy that combination treatment
has been suggested for colistin despite the fact
that A. baumanii heteroresistance to carbapenems
has also been described. Moreover, the clinical
implications of heteroresistance have not been
elucidated.
It should be emphasized that the potential
effect of antimicrobial heteroresistance on clinical
outcomes in patients with infections requires
further study [50]. Some experts hold that hetero-
resistance is an under-appreciated phenomenon
in both diagnosis and treatment of infectious
diseases. Also, available data concerning hetero-
resistance have provided some scientific argu-
ments in support of the possible advantages of
combination regimens in eradicating resistant
subpopulations [8].
CONCLUSIONS
Considering the preliminary data from clinical
studies that support the non-inferiority of colis-
tin monotherapy as compared with combination
therapy, the increased toxicity that combination
regimens may have, and the inadequate evi-
dence from animal studies that there is defini-
tive synergy between colistin and selected
antimicrobial agents, we believe that there is
an urgent need for clinicians in various parts of
the world to share their experience regarding
the comparative effectiveness and safety of
colistin monotherapy and colistin combination
therapy, even in the form of retrospective
studies. In addition, and most importantly, we
believe that the design and performance of
appropriately designed randomized controlled
trials comparing the effectiveness and safety of
colistin monotherapy with that of colistin com-
bination therapy would clarify the existing
uncertainty. Also, further reporting of the devel-
opment of resistant strains during colistin treat-
ment would help to answer the question of
whether the heteroresistance detected in in vitro
studies translates into an increased threat of
resistance in clinical practice when using colistin
monotherapy.
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